ANKEF1

Across TCGA pan-cancer cohorts, ANKEF1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ANKEF1 data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ANKEF1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANKEF1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

LIHC, UCEC, and SARC are the cancer types where ANKEF1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.033	0.779	<.001	42	view →
UCEC	OS	Median	All	0.968	0.649	.018	14	view →
SARC	OS	Median	All	0.022	0.861	<.001	6	view →
LGG	OS	Median	All	0.350	0.799	.022	3	view →
SKCM	DFS	Median	III,IV	0.755	0.462	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ANKEF1–LIHC (OS)

Open the LIHC breakdown →